Prospective Evaluation of Intrathecal Targeted Drug Delivery for Cancer Associated Pain

Completed

Conditions studied: Cancer Pain, Chronic Pain, Cancer Associated Pain, Neuropathic Pain

In brief

This Registry study will prospectively evaluate the differences in treatment outcomes in terms of pain intensity, pain interference, concomitant medication use, health-related quality of life, opioid adverse effects, and healthcare utilization between targeted drug delivery and conservative medication management only groups.

Key facts

Study ID

NCT05674240

Run by

Wake Forest University Health Sciences

People needed

30

Starts

2022-12-06

Expected to finish

2026-03-20

Last updated by the study team

2026-03-27

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age of 21 and older
• Uncontrolled cancer-associated pain (pain score of >5 on NRS) despite oral use of 60 mg/d morphine equivalent a week prior to screening
• Adverse side effects from long term opioid use defined as limiting or severely affecting patient's day to day function
• Life expectancy of > 3 months

You may not qualify if…

• Active infections
• Controlled pain without adverse side effects that are limiting day to day function
• Mechanical barriers
• Obstruction of Cerebrospinal Fluid (CSF)

Where it is running

• Advocate Aurora Health — Oshkosh, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.